Shenzhen Hepalink Pharmaceutical Co Ltd
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers finished dose pharmaceutical products,… Read more
Shenzhen Hepalink Pharmaceutical Co Ltd (002399) - Net Assets
Latest net assets as of September 2025: CN¥12.43 Billion CNY
Based on the latest financial reports, Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has net assets worth CN¥12.43 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥17.13 Billion) and total liabilities (CN¥4.70 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥12.43 Billion |
| % of Total Assets | 72.54% |
| Annual Growth Rate | 31.25% |
| 5-Year Change | 4.39% |
| 10-Year Change | 38.77% |
| Growth Volatility | 155.07 |
Shenzhen Hepalink Pharmaceutical Co Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Shenzhen Hepalink Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual net assets of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥12.20 Billion | +1.78% |
| 2023-12-31 | CN¥11.99 Billion | -3.38% |
| 2022-12-31 | CN¥12.41 Billion | +7.67% |
| 2021-12-31 | CN¥11.52 Billion | -1.42% |
| 2020-12-31 | CN¥11.69 Billion | +56.46% |
| 2019-12-31 | CN¥7.47 Billion | +19.64% |
| 2018-12-31 | CN¥6.24 Billion | -18.76% |
| 2017-12-31 | CN¥7.69 Billion | -4.97% |
| 2016-12-31 | CN¥8.09 Billion | -8.01% |
| 2015-12-31 | CN¥8.79 Billion | +5.27% |
| 2014-12-31 | CN¥8.35 Billion | +3.53% |
| 2013-12-31 | CN¥8.07 Billion | +0.28% |
| 2012-12-31 | CN¥8.05 Billion | +1.66% |
| 2011-12-31 | CN¥7.91 Billion | -1.36% |
| 2010-12-31 | CN¥8.02 Billion | +649.66% |
| 2009-12-31 | CN¥1.07 Billion | +247.68% |
| 2008-12-31 | CN¥307.83 Million | +110.21% |
| 2007-12-31 | CN¥146.44 Million | +60.34% |
| 2006-12-31 | CN¥91.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shenzhen Hepalink Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5645.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.19 Billion | 18.03% |
| Common Stock | CN¥1.47 Billion | 12.08% |
| Other Comprehensive Income | CN¥962.56 Million | 7.92% |
| Other Components | CN¥7.53 Billion | 61.97% |
| Total Equity | CN¥12.15 Billion | 100.00% |
Shenzhen Hepalink Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Shenzhen Hepalink Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Medplus Health Services Limited
NSE:MEDPLUS
|
$659.03 Million |
|
Jiangsu SINOJIT Wind Energy Technology Co Ltd
SHG:601218
|
$659.45 Million |
|
URW (STAPL.SHS CDI)EO-05
F:UBLB
|
$659.78 Million |
|
Alstom PK
PINK:ALSMY
|
$659.84 Million |
|
Wutong Holding Group Co Ltd
SHE:300292
|
$658.70 Million |
|
Medco Energi Internasional Tbk
JK:MEDC
|
$658.15 Million |
|
Chongqing Landai Powertrain Corp Ltd
SHE:002765
|
$657.99 Million |
|
MONTROSE ENV.GRP -000004
F:5MO
|
$657.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shenzhen Hepalink Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,913,149,195 to 12,148,672,778, a change of 235,523,583 (2.0%).
- Net income of 646,742,000 contributed positively to equity growth.
- Dividend payments of 159,901,320 reduced retained earnings.
- Other comprehensive income increased equity by 804,103,075.
- Other factors decreased equity by 1,055,420,172.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥646.74 Million | +5.32% |
| Dividends Paid | CN¥159.90 Million | -1.32% |
| Other Comprehensive Income | CN¥804.10 Million | +6.62% |
| Other Changes | CN¥-1.06 Billion | -8.69% |
| Total Change | CN¥- | 1.98% |
Book Value vs Market Value Analysis
This analysis compares Shenzhen Hepalink Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.38x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 35.98x to 1.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.32 | CN¥11.39 | x |
| 2007-12-31 | CN¥0.51 | CN¥11.39 | x |
| 2008-12-31 | CN¥1.07 | CN¥11.39 | x |
| 2009-12-31 | CN¥0.93 | CN¥11.39 | x |
| 2010-12-31 | CN¥12.93 | CN¥11.39 | x |
| 2011-12-31 | CN¥6.13 | CN¥11.39 | x |
| 2012-12-31 | CN¥6.22 | CN¥11.39 | x |
| 2013-12-31 | CN¥6.24 | CN¥11.39 | x |
| 2014-12-31 | CN¥6.46 | CN¥11.39 | x |
| 2015-12-31 | CN¥6.88 | CN¥11.39 | x |
| 2016-12-31 | CN¥6.36 | CN¥11.39 | x |
| 2017-12-31 | CN¥6.08 | CN¥11.39 | x |
| 2018-12-31 | CN¥4.87 | CN¥11.39 | x |
| 2019-12-31 | CN¥5.89 | CN¥11.39 | x |
| 2020-12-31 | CN¥8.55 | CN¥11.39 | x |
| 2021-12-31 | CN¥7.78 | CN¥11.39 | x |
| 2022-12-31 | CN¥8.39 | CN¥11.39 | x |
| 2023-12-31 | CN¥8.12 | CN¥11.39 | x |
| 2024-12-31 | CN¥8.28 | CN¥11.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shenzhen Hepalink Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.32%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.30%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.43x
- Recent ROE (5.32%) is below the historical average (16.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 52.43% | 17.24% | 0.80x | 3.82x | CN¥38.75 Million |
| 2007 | 46.55% | 22.77% | 1.16x | 1.76x | CN¥53.52 Million |
| 2008 | 52.43% | 37.08% | 0.75x | 1.88x | CN¥130.61 Million |
| 2009 | 75.98% | 36.38% | 1.62x | 1.29x | CN¥702.57 Million |
| 2010 | 15.13% | 31.39% | 0.47x | 1.02x | CN¥410.32 Million |
| 2011 | 7.96% | 24.94% | 0.31x | 1.02x | CN¥-159.56 Million |
| 2012 | 7.84% | 35.44% | 0.21x | 1.04x | CN¥-171.76 Million |
| 2013 | 3.97% | 20.97% | 0.18x | 1.04x | CN¥-481.27 Million |
| 2014 | 4.09% | 17.27% | 0.20x | 1.20x | CN¥-488.70 Million |
| 2015 | 6.65% | 25.29% | 0.19x | 1.40x | CN¥-292.13 Million |
| 2016 | 4.98% | 17.55% | 0.18x | 1.62x | CN¥-400.23 Million |
| 2017 | 2.59% | 6.92% | 0.22x | 1.74x | CN¥-561.38 Million |
| 2018 | 9.75% | 12.28% | 0.35x | 2.25x | CN¥-15.34 Million |
| 2019 | 14.42% | 22.91% | 0.30x | 2.07x | CN¥324.65 Million |
| 2020 | 8.85% | 19.21% | 0.28x | 1.64x | CN¥-132.73 Million |
| 2021 | 2.11% | 3.78% | 0.33x | 1.67x | CN¥-900.35 Million |
| 2022 | 5.91% | 10.16% | 0.34x | 1.69x | CN¥-503.67 Million |
| 2023 | -6.57% | -14.42% | 0.28x | 1.61x | CN¥-1.97 Billion |
| 2024 | 5.32% | 12.30% | 0.30x | 1.43x | CN¥-568.13 Million |
Industry Comparison
This section compares Shenzhen Hepalink Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shenzhen Hepalink Pharmaceutical Co Ltd (002399) | CN¥12.43 Billion | 52.43% | 0.38x | $658.84 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |